Targeting SHP2 phosphatase in breast cancer overcomes RTK-mediated resistance to PI3K inhibitors.

Guus J J E HeynenKamil LisekRegina VogelAnnika Wulf-GoldenbergJoshua AlcanizElodie MontaudonElisabetta MarangoniWalter Birchmeier

Published in: Breast cancer research : BCR (2022)

Our results highlight the importance of SHP2 as a player in resistance to PI3K inhibitors. Combination treatment with PI3K and SHP2 inhibitors could pave the way for significant improvements in therapies for breast cancer.

Keyphrases

cancer therapy
drug delivery